Core Viewpoint - The strategic collaboration between Innovent Biologics and Eli Lilly aims to advance global research and development of innovative drugs in oncology and immunology, with Innovent leading the projects in China while Eli Lilly retains exclusive rights outside Greater China [1]. Group 1: Partnership Details - Innovent Biologics will receive an upfront payment of $350 million and is eligible for up to $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [1]. - The collaboration marks the seventh partnership between Innovent and Eli Lilly, highlighting a long-standing relationship that has evolved from capital investment to product commercialization [2]. - Innovent has previously collaborated with Eli Lilly on multiple projects, including agreements that set records for cooperation amounts between multinational and local pharmaceutical companies [2][3]. Group 2: Financial Performance - In 2020, Innovent achieved total revenue of 3.844 billion yuan, a year-on-year increase of 266.9%, with product revenue reaching 2.368 billion yuan, a 133.0% increase [3]. - The company anticipates total product revenue of approximately 11.9 billion yuan in 2025, marking a 45% year-on-year growth and the first time surpassing 10 billion yuan in product revenue [7]. - Innovent aims to achieve a product revenue scale of 20 billion yuan by 2027 and plans to advance five core pipelines into global Phase III clinical trials by 2030 [7]. Group 3: Globalization Strategy - Innovent's collaboration model has become a crucial component of its product pipeline, with 18 approved products, many developed through partnerships [6]. - The company is focusing on reducing reliance on external collaborations while enhancing its core R&D capabilities [10]. - Innovent's internationalization journey reflects the broader trend of Chinese innovative pharmaceutical companies transitioning to global markets, emphasizing the need for quality and originality in innovation [10].

2026年开年以来，国产创新药BD出海延续火热态势，此前石药-阿斯利康（185亿美元）、荣昌-艾伯维 （56亿美元）等重磅合作充分印证国产创新药国际竞争力提升，信达生物本次88.5亿美元大动作为创新 药出海再添一把火！ | 转让方 | 受让方 | 2026年以来中国创新药出海授权交易一览(部分 最高里程碑付款 | 首付款 | | --- | --- | --- | --- | | 石药集团 | 阿斯利康 | 173亿美元 | 12亿美元 | | 荣昌生物 | 艾伯维 | 49.5亿美元 | 6.5亿美元 | | 泽璟制药 | 艾伯维 | 11.35亿美元 | 1亿美元 | | 灰龍ણ | AirNexis | 9.55亿美元 | 1.08亿美元 | | 先声药业 | 勃林格殷格翰 | 10.16亿欧元 | 4200万欧元 | | 宜联生物 | 器联 | 5.7亿美元 | 未单独披露 | | 数据截至2026年1月30日。 | | | | 值得一提的是，港股通创新药板块当前处于阶段低位，港股通创新药ETF（520880）场内价格于上周创 下上市以来新低。低位吸纳创新药便宜筹码，认准港股通创新药ETF（52088 ...

每经AI快讯，信达生物(01801.HK)高开逾4%，截至发稿，涨4.65%，报83.2港元，成交额1364.48万港 元。 ...

Core Viewpoint - The strategic collaboration between Innovent Biologics and Eli Lilly aims to advance the global research and development of innovative drugs in oncology and immunology, marking a significant milestone in their long-term partnership [1] Group 1: Financial Aspects - Innovent Biologics received an upfront payment of $350 million as part of the agreement [1] - The company is eligible for up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [1] - Innovent Biologics retains the rights to all products in Greater China while Eli Lilly secures exclusive global development and commercialization rights outside this region [1] Group 2: Strategic Collaboration - This agreement represents the seventh collaboration between Innovent Biologics and Eli Lilly, further deepening their productive partnership [1] - The collaboration leverages Innovent's established antibody technology platform and efficient clinical capabilities to lead projects from drug discovery to clinical concept verification in China [1] - Eli Lilly will benefit from the global exclusive development and commercialization rights for the relevant projects outside Greater China [1]

根据合作协议，双方将发挥互补优势，加快推进创新药物的全球研发工作。信达生物依托自身成熟的抗 体技术平台及高效的临床能力，将主导相关项目从药物发现至中国临床概念验证（二期临床试验完成） 的研发工作；礼来获得相关项目在大中华区以外的全球独家开发与商业化许可，信达生物保留相关项目 在大中华区的全部权利。 消息面上，信达生物公告，与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发进 程。根据协议条款，信达生物将获得3.5亿美元首付款；在达成后续特定里程碑事件后，信达生物还有 资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。此外，信达生物有权就各产品在大中 华区以外的净销售额获得梯度的销售分成。本次协议为双方第七次合作，进一步深化了双方长期且富有 成效的合作伙伴关系。 智通财经APP获悉，信达生物(01801)高开逾4%，截至发稿，涨4.65%，报83.2港元，成交额1364.48万港 元。 ...

Group 1 - The State Council meeting on February 6 emphasized the need to innovate and improve policy measures to promote effective investment, focusing on major projects in infrastructure, urban renewal, public services, and emerging industries [8] - Eight departments, including the People's Bank of China, reiterated the prohibition of virtual currencies, emphasizing that they do not have the same legal status as fiat currencies and outlining clear policy requirements for stablecoins and tokenization of real-world assets [8] - On February 7, China successfully launched a reusable experimental spacecraft using the Long March 2F rocket, aimed at validating reusable spacecraft technology for peaceful space utilization [8] Group 2 - The People's Bank of China reported that as of January 2026, the country's gold reserves stood at 74.19 million ounces, marking a continuous increase for the 15th month [9] - The China Securities Regulatory Commission released a notice on February 6 regarding the selection direction for provincial-level research topics, focusing on enhancing the inclusiveness and adaptability of the capital market during the 14th Five-Year Plan period [9] - The Shanghai and Shenzhen Stock Exchanges revised and published regulatory guidelines for underwriting violations, aiming to enhance regulatory practices and ensure effective supervision [10] Group 3 - Longyun Co. will resume trading on February 9, planning to acquire 58% of Yuheng Film Industry [12] - Jihua Group will also resume trading on February 9, with plans for changes in its controlling shareholder and actual controller [12] - Xinwangda reached a settlement in a lawsuit involving over 2.3 billion yuan, while other companies like ST Pava and Aihua Long are facing legal challenges and investigations [12][12]

Macro and Strategy Research - In January 2026, the central bank's liquidity net injection reached 1.2 trillion yuan, an increase of nearly 400 billion yuan compared to December 2025, indicating a supportive stance on liquidity [3] - The issuance of interest rate bonds in January 2026 totaled 2.7 trillion yuan, a year-on-year increase of over 600 billion yuan, with significant growth in government bonds, local bonds, and policy financial bonds [4] - The bond market outlook suggests that if the liquidity remains stable, interest rate bonds may show a strong oscillation pattern, with a focus on 3-year bonds and ultra-long-term bonds for potential gains [5] Industry Research - The pharmaceutical and biotechnology industry is seeing a concentration of performance forecasts, with key developments including the approval of new drugs and significant partnerships among companies [10][11] - The SW pharmaceutical and biotechnology index saw a decline of 0.97% in the week of January 30 to February 5, 2026, with the industry’s price-to-earnings ratio at 51.01 times, reflecting a 261% premium over the CSI 300 index [11] - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, as well as monitoring companies that are expected to show a turnaround in performance [12]

Core Viewpoint - Cinda Biologics has entered into a strategic collaboration with Eli Lilly to advance the global development of innovative drugs in the oncology and immunology fields [1] Group 1: Collaboration Details - Cinda Biologics will lead the projects from drug discovery to clinical concept validation in China, specifically through the completion of Phase II clinical trials [1] - Eli Lilly will obtain exclusive development and commercialization rights for the related projects outside of Greater China, while Cinda Biologics retains all rights within Greater China [1] Group 2: Financial Terms - Cinda Biologics will receive an upfront payment of $350 million [1] - Upon achieving specific subsequent milestones, Cinda Biologics is eligible for up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization [1] - Cinda Biologics will also have the right to receive a tiered sales share based on net sales outside of Greater China for each product [1]

Core Insights - Innovent Biologics has signed a deal with Eli Lilly to jointly develop experimental medicines targeting cancer and immune-related diseases, marking the continuation of a partnership that has lasted over a decade [4] Company Developments - The new agreement represents the seventh collaboration between Innovent Biologics and Eli Lilly, indicating a strong and ongoing relationship in the biopharmaceutical sector [4]

Core Viewpoint - The strategic collaboration between Innovent Biologics and Eli Lilly aims to advance global research and development of innovative drugs in oncology and immunology, marking a significant milestone in their long-term partnership [2][3]. Group 1: Strategic Collaboration Details - Innovent Biologics will receive an upfront payment of $350 million, with potential milestone payments totaling up to approximately $8.5 billion based on specific future achievements [2]. - The agreement allows Innovent to retain all rights to the products in Greater China while granting Eli Lilly exclusive global development and commercialization rights outside this region [2]. - This partnership represents the seventh collaboration between the two companies, enhancing their productive relationship and establishing a new cooperative model for global drug development [2]. Group 2: Company Performance and Future Outlook - Innovent Biologics is expected to achieve total product revenue exceeding 11.9 billion RMB in 2025, reflecting a year-on-year growth rate of approximately 45% [3]. - In the fourth quarter of 2025, the company anticipates total product revenue of around 3.3 billion RMB, with a year-on-year increase of over 60% [3]. - The company is focusing on accelerating global clinical development of its innovative pipeline, particularly in next-generation tumor immunotherapy (IO) and antibody-drug conjugates (ADC) [3]. Group 3: Market Position - As of February 6, 2023, Innovent Biologics' stock closed at 79.5 HKD per share, with a market capitalization of 137.9 billion HKD [4].